Showing 4691-4700 of 5646 results for "".
- Clots, Strokes And Rashes. Is COVID-19 A Disease Of The Blood Vessels?https://modernod.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/Whether it’s strange rashes on the toes or blood clots in the brain, the widespread ravages of COVID-19 have increasingly led researchers to focus on how the novel coronavirus sabotages the body’s blood vessels, according to an NPR
- Technique to Regenerate Optic Nerve Offers Hope for Future Glaucoma Treatmenthttps://modernod.com/news/technique-to-regenerate-optic-nerve-offers-hope-for-future-glaucoma-treatment/2478496/Scientists have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, according to a Medical Xpress report. </
- Staar Surgical Begins Commercialization of EVO Viva Presbyopia Correcting Lenshttps://modernod.com/news/staar-surgical-begins-commercialization-of-evo-viva-presbyopia-correcting-lens/2478495/Staar Surgical announced the initial commercialization of its EVO Viva presbyopia correcting lens including the first patient implant. “The first patient received his EVO Viva lenses on October 23 in Belgium from Dr. Erik Mertens, and we are delighted to hear from Dr. Mertens that the pati
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseaseshttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-of-open-label-safety-study-for-lytenava-for-retinal-diseases/2478490/Outlook Therapeutics announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/Lytenava (NORSE THREE). Patient enrollment for the study was completed in less than 1 month, ahead of the planned 4-month enrollment schedule.
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for
- Internal Documents Reveal COVID-19 Hospitalization Data The Government Keeps Hiddenhttps://modernod.com/news/internal-documents-reveal-covid-19-hospitalization-data-the-government-keeps-hidden/2478485/As coronavirus cases rise swiftly around the country, surpassing both the spring and summer surges, health officials brace for a coming wave of hospitalizations and deaths. Knowing which hospitals in which communities are reaching capacity could be key to an effective response to the growing cris
- Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy for Dry AMD Via Orbit SDShttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-for-dry-amd-via-orbit-subretinal-delivery-system/2478480/Gyroscope Therapeutics announced that the first surgery using its proprietary Orbit Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been condu
- Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseaseshttps://modernod.com/news/ocumension-therapeutics-strengthens-pipeline-for-posterior-segment-eye-diseases/2478482/Ocumension Therapeutics announced that the company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology, a wholly-owned subsidiary of Luye Pharma Group, to jointly develop OT-702 (LY09004), a biosimilar to Eylea (aflibercept). Ocumension has
- RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trialhttps://modernod.com/news/regenerx-joint-venture-enrolls-last-subject-in-phase-3-dry-eye-trial/2478468/RegeneRx Biopharmaceuticals announced that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome. Completion of treatment and follow-up for the last subject is anticipated to be by the end of Novem